Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial-Reference-Cited by-同舟云学术

Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial

Published:2020-03 Issue: Volume:17 Page:100537
ISSN:2451-8654
Container-title:Contemporary Clinical Trials Communications
language:en
Short-container-title:Contemporary Clinical Trials Communications

Author:

Hasan Alkomiet,Roeh Astrid,Leucht Stefan,Langguth Berthold,Hansbauer Maximilian,Oviedo-Salcedo Tatiana,Kirchner Sophie K.,Papazova Irina^ORCID,Löhrs Lisa,Wagner Elias^ORCID,Maurus Isabel,Strube Wolfgang,Rossner Moritz J.^ORCID,Wehr Michael C.,Bauer Ingrid,Heres Stephan,Leucht Claudia,Kreuzer Peter M.,Zimmermann Stephanie,Schneider-Axmann Thomas,Görlitz Thomas,Karch Susanne,Egert-Schwender Silvia,Schossow Beate,Rothe Philipp,Falkai Peter

Funder

Stanley Medical Research Institute

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference51 articles.

1. From neuroleptics to neuroscience and from Pavlov to psychotherapy: more than just the "emperor's new treatments" for mental illnesses?;Margraf;EMBO Mol. Med.,2016

2. World federation of societies of biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance;Hasan;World J. Biol. Psychiatr.,2012

3. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia;Carbon;CNS Spectr.,2014

4. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors;Leucht;Am. J. Psychiatr.,2017

5. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis;Helfer;Am. J. Psychiatr.,2016

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists;iScience;2024-02

2. Challenges, unmet needs and future directions – a critical evaluation of the clinical trial landscape in schizophrenia research;Expert Review of Clinical Pharmacology;2023-12-18

3. Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric Trial;Pharmacopsychiatry;2023-07-28

4. Neuregulin-1/PI3K signaling effects on oligodendrocyte proliferation, remyelination and behaviors deficit in a male mouse model of ischemic stroke;Experimental Neurology;2023-04

5. Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial;Journal of Neural Transmission;2022-11-19